EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression

Filip Marković iD, Zlatan Bojić, Mihailo Stjepanović iD, Milica Kontić iD

Cancers · 03.04.2026 · 18 (7) · 1153

DOI: 10.3390/cancers18071153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.04.2026. Verfasst von Filip Marković und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Pulmonology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor monotherapy targeting the PD-1/PD-L1 axis is a standard first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) and high PD-L1 expression. However, comparative real-world data evaluating PD-1 versus PD-L1 inhibitor monotherapy in this population remain limited.

Methods

We conducted a retrospective, single-center real-world analysis of patients with metastatic NSCLC and high PD-L1 expression who initiated first-line immune checkpoint inhibitor monotherapy between May 2024 and January 2025. Patients were treated with either pembrolizumab (PD-1 inhibitor) or atezolizumab (PD-L1 inhibitor) as monotherapy. Progression-free survival (PFS) was estimated using the Kaplan–Meier method and compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression models were applied to identify clinical factors associated with PFS.

Results

A total of 125 patients were included, of whom 73 received pembrolizumab and 52 received atezolizumab. The median PFS was numerically longer in patients treated with pembrolizumab compared with atezolizumab (9.93 vs. 5.33 months), although this difference did not reach statistical significance (HR 1.14, 95% CI 0.74–1.74; p = 0.559). Poor performance status (ECOG PS 2) was independently associated with inferior PFS (HR 3.22, 95% CI 2.02–5.12), whereas very high PD-L1 expression (TPS 90–100%) was independently associated with improved PFS (HR 0.57, 95% CI 0.35–0.93).

Conclusions

In this real-world cohort, pembrolizumab was associated with numerically longer PFS than atezolizumab; however, this difference was not statistically significant. Outcomes were primarily driven by baseline clinical factors, particularly performance status and the degree of PD-L1 expression. Larger cohorts with longer follow-up are warranted to clarify potential differences and assess long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

atezolizumabimmune checkpoint inhibitornon-small cell lung cancerpembrolizumabreal-world data

Autor:innen und Institutionen

  • Clinic for Pulmonology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
  • Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

ORCID-Profile: Filip Marković, Mihailo Stjepanović, Milica Kontić

Zitieren

APA

Marković, F., Bojić, Z., Stjepanović, M., & Kontić, M. (2026). Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. Cancers, 18(7), 1153. https://doi.org/10.3390/cancers18071153

Vancouver

Marković F, Bojić Z, Stjepanović M, Kontić M. Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. Cancers. 2026;18(7):1153. doi:10.3390/cancers18071153

BibTeX
@article{Markovi2026,
  author = {Marković, Filip and Bojić, Zlatan and Stjepanović, Mihailo and Kontić, Milica},
  title = {Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1153},
  doi = {10.3390/cancers18071153}
}
Kostenlos starten →